PT  - JOURNAL ARTICLE
AU  - Tammy L. Domanski
AU  - Csaba Finta
AU  - James R. Halpert
AU  - Peter G. Zaphiropoulos
TI  - cDNA Cloning and Initial Characterization of CYP3A43, a Novel Human Cytochrome P450
AID  - 10.1124/mol.59.2.386
DP  - 2001 Feb 01
TA  - Molecular Pharmacology
PG  - 386--392
VI  - 59
IP  - 2
4099  - http://molpharm.aspetjournals.org/content/59/2/386.short
4100  - http://molpharm.aspetjournals.org/content/59/2/386.full
SO  - Mol Pharmacol2001 Feb 01; 59
AB  - The RACE amplification technology was used on a novel CYP3A-like exon 1 sequence detected during the reverse transcriptase/polymerase chain reaction analysis of human CYP3A gene expression. This resulted in the identification of cDNAs encompassing the complete coding sequence of a new member of the CYP3A gene subfamily, CYP3A43. Interestingly, the majority of the cDNAs identified were characterized by alternative splicing events such as exon skipping and complete or partial intron inclusion.CYP3A43 expression was detected in liver, kidney, pancreas, and prostate. The amino acid sequence is 75% identical to that of CYP3A4 and CYP3A5 and 71% identical to CYP3A7. CYP3A43 differs from CYP3A4 at six amino acid residues, found within the putative substrate recognition sites of CYP3A4, that are known to be determinants of substrate selectivity. The N terminus of CYP3A43 was modified for efficient expression of the protein in Escherichia coli, and a 6X histidine tag was added at the C terminus to facilitate purification. CYP3A43 gave a reduced carbon monoxide difference spectra with an absorbance maximum at 450 nm. The level of heterologous expression was significantly lower than that observed for CYP3A4 and CYP3A5. Immunoblot analyses revealed that CYP3A43 comigrates with CYP3A4 in polyacrylamide gel electrophoresis but does separate from CYP3A5. Monooxygenase assays were performed under a variety of conditions, several of which yielded reproducible, albeit low, testosterone hydroxylase activity. The findings from this study demonstrate that there is a novel CYP3A member expressed in human tissues, although its relative contribution to drug metabolism has yet to be ascertained.